Melflufen in multiple myeloma: the conclusion matters - Authors' reply
Lancet Haematol
.
2022 Apr;9(4):e244-e245.
doi: 10.1016/S2352-3026(22)00071-0.
Authors
Fredrik H Schjesvold
1
,
Nicolaas A Bakker
2
,
Pieter Sonneveld
3
Affiliations
1
Department of Hematology, Oslo Myeloma Center, Oslo University Hospital, Oslo N-0450, Norway. Electronic address: fredrikschjesvold@gmail.com.
2
Oncopeptides AB, Stockholm, Sweden.
3
Erasmus MC Cancer Institute, Rotterdam, Netherlands.
PMID:
35358436
DOI:
10.1016/S2352-3026(22)00071-0
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Melphalan / analogs & derivatives
Multiple Myeloma* / drug therapy
Phenylalanine / analogs & derivatives
Substances
melflufen
Phenylalanine
Melphalan